Quarterly ResultAug 13, 2026, 04:14 PM
Onconetix Q2 Net Loss $2.87M; Going Concern Doubt Raised
AI Summary
Onconetix, Inc. reported a net loss of $2.87 million for Q2 2026 and $7.08 million for the six months ended June 30, 2026. The company's cash balance was $5.94 million as of June 30, 2026, and it incurred significant goodwill impairment losses. Management raised substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and the need for additional financing, despite recent Series F Preferred Stock proceeds.
Key Highlights
- Net loss for Q2 2026 was $2.87 million, compared to $2.37 million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $7.08 million, compared to $10.92 million in the prior year.
- Revenue for Q2 2026 was $17,120, down from $106,494 in Q2 2025.
- Cash balance as of June 30, 2026, was $5.94 million, with an accumulated deficit of $138.3 million.
- Goodwill impairment losses totaled $0.49 million for Q2 2026 and $8.62 million for the six months ended June 30, 2026.
- Net cash used in operating activities for the six months ended June 30, 2026, was $4.04 million.
- Company raised approximately $30.2 million gross proceeds from Series F Preferred Stock in July 2026, receiving $0.25 million net cash.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
Price Impact
More from ONCO